PE20130523A1 - NEW PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE - Google Patents

NEW PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE

Info

Publication number
PE20130523A1
PE20130523A1 PE2012001634A PE2012001634A PE20130523A1 PE 20130523 A1 PE20130523 A1 PE 20130523A1 PE 2012001634 A PE2012001634 A PE 2012001634A PE 2012001634 A PE2012001634 A PE 2012001634A PE 20130523 A1 PE20130523 A1 PE 20130523A1
Authority
PE
Peru
Prior art keywords
receptor
peptide
preparation
methods
glucagon
Prior art date
Application number
PE2012001634A
Other languages
Spanish (es)
Inventor
Jorge Alsina-Fernandez
Krister Bengt Bokvist
Lili Guo
John Philip Mayer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44041636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130523(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20130523A1 publication Critical patent/PE20130523A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN POLIPEPTIDO CARACTERIZADO PORQUE COMPRENDE LA SECUENCIA SEC ID Nº 1 DONDE: Xaa1 EN LA POSICION 22 ES NAFTILALANINA (NAL) O FENILO; Xaa2 Y Xaa3 ESTAN AUSENTES O SON CADA UNO CYS PEGILADOS CON UN POLIETILENGLICOL LINEAL DE 18 A 20 KDa. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO PEPTIDO PRESENTA ACTIVIDAD TANTO PARA EL RECEPTOR DEL PEPTIDO INSULINOTROPICO DEPENDIENTE DE GLUCOSA (GIP-R) COMO PARA EL RECEPTOR DEL PEPTIDO-1 SIMILAR AL GLUCAGON (GLP-1-R) Y ES SELECTIVO SOBRE EL RECEPTOR DEL GLUCAGON (GLUC-R) SIENDO UTIL EN EL TRATAMIENTO DE LA DIABETES MELLITUS.REFERS TO A POLYPEPTIDE CHARACTERIZED BECAUSE IT INCLUDES SEQUENCE SEQ ID NO: 1 WHERE: Xaa1 AT POSITION 22 IS NAFTILALANINE (NAL) OR PHENYL; Xaa2 AND Xaa3 ARE EACH ABSENT OR CYS STICKED WITH A LINEAR POLYETHYLENE GLYCOL OF 18 TO 20 KDa. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION. SAID PEPTIDE PRESENTS ACTIVITY FOR BOTH THE GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP-R) AND FOR THE GLUCAGON-SIMILAR PEPTIDE-1 RECEPTOR (GLP-1-R) AND IS SELECTIVE ON THE GLUCAGON RECEPTOR (GLUC-R) BEING USEFUL IN THE TREATMENT OF DIABETES MELLITUS.

PE2012001634A 2010-03-26 2011-03-23 NEW PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE PE20130523A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31785010P 2010-03-26 2010-03-26

Publications (1)

Publication Number Publication Date
PE20130523A1 true PE20130523A1 (en) 2013-04-25

Family

ID=44041636

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001634A PE20130523A1 (en) 2010-03-26 2011-03-23 NEW PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE

Country Status (25)

Country Link
US (1) US8815811B2 (en)
EP (1) EP2552471B1 (en)
JP (1) JP5887335B2 (en)
KR (1) KR101407775B1 (en)
CN (1) CN102821779B (en)
AR (1) AR080592A1 (en)
AU (1) AU2011232597B2 (en)
BR (1) BR112012024373A2 (en)
CA (1) CA2794664A1 (en)
CL (1) CL2012002635A1 (en)
CO (1) CO6630128A2 (en)
CR (1) CR20120457A (en)
DO (1) DOP2012000244A (en)
EA (1) EA022489B1 (en)
EC (1) ECSP12012181A (en)
ES (1) ES2568796T3 (en)
GT (1) GT201200263A (en)
MA (1) MA34077B1 (en)
MX (1) MX2012011127A (en)
PE (1) PE20130523A1 (en)
SG (1) SG184289A1 (en)
TN (1) TN2012000432A1 (en)
TW (1) TWI535450B (en)
WO (1) WO2011119657A1 (en)
ZA (1) ZA201206832B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959986B1 (en) 2005-11-07 2014-07-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
BRPI0807728A2 (en) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp glucagon / glp-1 receptor co-agonists
ES2558155T3 (en) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compounds showing glucacon antagonist activity and GLP-1 agonist
ES2509883T3 (en) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Glucagon antagonists
CN102088989B (en) 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 Glucagon analogs exhibiting enhanced solubility and stability physiological pH buffers
JP6108659B2 (en) 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ GIP-based mixed agonist for the treatment of metabolic diseases and obesity
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
PE20120332A1 (en) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp PEPTIDE PROPHARS FROM THE GLUCAGON SUPERFAMILY BASED ON AMIDA
MX2011013625A (en) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds.
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CA2788304A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
MX2012014576A (en) 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs.
WO2012088116A2 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
EP2723367B1 (en) 2011-06-22 2017-05-03 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
JP6184404B2 (en) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Glucagon / GLP-1 receptor co-agonist
IN2014CN02448A (en) 2011-09-23 2015-06-19 Novo Nordisk As
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
KR102184241B1 (en) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Gip-glp-1 dual agonist compounds and methods
SG11201407860PA (en) 2012-06-14 2014-12-30 Sanofi Sa Exendin-4 peptide analogues
JP6311708B2 (en) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analog showing GIP receptor activity
CN104662038B (en) 2012-07-23 2018-11-06 西兰制药公司 Glucagon analogue
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
CN104870009B (en) * 2012-12-21 2021-05-18 赛诺菲 Functionalized exendin-4 derivatives
SG11201506804VA (en) 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of hydantoin containing peptide products
WO2014147129A1 (en) 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
WO2014161835A1 (en) 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
MX362275B (en) * 2013-04-18 2019-01-10 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use.
PE20151770A1 (en) 2013-05-28 2015-12-11 Takeda Pharmaceutical PEPTIDIC COMPOUND
KR102569036B1 (en) 2013-10-17 2023-08-23 질랜드 파마 에이/에스 Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CN105849122B (en) * 2013-11-06 2021-04-30 西兰制药公司 GIP-GLP-1 dual agonist compounds and methods
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) * 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
CN106536547A (en) 2014-06-04 2017-03-22 诺和诺德股份有限公司 GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2716985C2 (en) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Gip agonist compounds and methods
JOP20200119A1 (en) * 2015-01-09 2017-06-16 Lilly Co Eli Gip and glp-1 co-agonist compounds
RU2735762C2 (en) 2015-04-16 2020-11-06 Зилэнд Фарма А/С Acylated glucagon analogue, use thereof and methods of producing
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
TWI622596B (en) 2015-10-26 2018-05-01 美國禮來大藥廠 Glucagon receptor agonists
CN109477094B (en) 2016-05-24 2022-04-26 武田药品工业株式会社 Peptide compounds
EP3551202B1 (en) 2016-12-06 2024-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (en) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co Peptide compound
TWI744579B (en) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 Incretin analogs and uses thereof
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
EP3699187A1 (en) * 2019-02-21 2020-08-26 Universite D'angers Peptide targeting gip and glp-2 receptors for treating bone disorders
CN110684082B (en) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 GIP and GLP-1 dual-agonist polypeptide compound, pharmaceutically acceptable salt and application
MX2022009149A (en) * 2020-01-23 2022-12-15 Lilly Co Eli Gip/glp1 co-agonist compounds.
CA3174635A1 (en) 2020-03-06 2021-09-10 Sanofi Peptides as selective gip receptor agonists
CA3175135A1 (en) * 2020-03-11 2021-09-16 Anygen Co., Ltd. Compound for anti-diabetes and anti-obesity
CN117866048A (en) * 2021-05-28 2024-04-12 广东众生睿创生物科技有限公司 Preparation and application of polypeptide
EP4345105A1 (en) * 2021-06-01 2024-04-03 Nanjing Zhine Medicine Technology Co., Ltd. Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof
AU2022339059A1 (en) 2021-09-06 2024-05-02 Sanofi New peptides as potent and selective gip receptor agonists
KR20230037391A (en) * 2021-09-09 2023-03-16 애니젠 주식회사 Composition for preventing or treating inflammatory bowl disease comprising novel compound
CN118234505A (en) * 2021-11-19 2024-06-21 南京明德新药研发有限公司 Binding peptides and uses thereof
WO2024059674A1 (en) 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2006121904A1 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
JP2008539735A (en) * 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン Glucagon-like peptide 1 (GLP-1) receptor antagonists and methods for their pharmacological use
JP6108659B2 (en) * 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ GIP-based mixed agonist for the treatment of metabolic diseases and obesity
KR20130133103A (en) * 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
EP2328922A4 (en) * 2008-08-07 2013-01-02 Ipsen Pharma Sas Analogues of glucose-dependent insulinotropic polypeptide
MX2011013625A (en) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds.
CA2788304A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity

Also Published As

Publication number Publication date
ECSP12012181A (en) 2012-11-30
EA022489B1 (en) 2016-01-29
AR080592A1 (en) 2012-04-18
CA2794664A1 (en) 2011-09-29
GT201200263A (en) 2013-12-05
CO6630128A2 (en) 2013-03-01
TWI535450B (en) 2016-06-01
KR101407775B1 (en) 2014-06-17
EA201270723A1 (en) 2013-01-30
JP2013523647A (en) 2013-06-17
TW201201829A (en) 2012-01-16
DOP2012000244A (en) 2013-02-15
US8815811B2 (en) 2014-08-26
AU2011232597A1 (en) 2012-08-30
AU2011232597B2 (en) 2015-01-29
BR112012024373A2 (en) 2017-01-10
SG184289A1 (en) 2012-11-29
CL2012002635A1 (en) 2012-12-21
WO2011119657A1 (en) 2011-09-29
MA34077B1 (en) 2013-03-05
CN102821779B (en) 2015-03-11
US20110237503A1 (en) 2011-09-29
EP2552471A1 (en) 2013-02-06
ZA201206832B (en) 2014-03-26
JP5887335B2 (en) 2016-03-16
ES2568796T3 (en) 2016-05-04
CN102821779A (en) 2012-12-12
TN2012000432A1 (en) 2014-01-30
KR20120133402A (en) 2012-12-10
EP2552471B1 (en) 2016-03-16
CR20120457A (en) 2012-10-16
MX2012011127A (en) 2012-10-15

Similar Documents

Publication Publication Date Title
PE20130523A1 (en) NEW PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE
NZ597580A (en) Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
AR081200A1 (en) INSULIN FORMULATIONS OF PROLONGED ACTION
CO7200249A2 (en) Long-acting oxintomodulin variants and their production methods
PE20140724A1 (en) GLUCAGON / GLP-1 RECEPTOR COAGONISTS
PE20100056A1 (en) GLUCAGON ANALOGS AS GIP AGONISTS
CO6660484A2 (en) Glucagon analogues
CL2012001685A1 (en) Peptide analog of oxyntomodulin, wherein the c-terminal amino acid is optionally amidated; pharmaceutical composition comprising it; and its use in the preparation of a medicament for the treatment of non-insulin dependent diabetes or obesity.
PE20240686A1 (en) PEPTIDES DERIVED FROM OXYNTOMODULIN WITH ACTIVITY ON THE GLUCAGON RECEPTOR AND THE GLUCAGON-LIKE PEPTIDE RECEPTOR TYPE 1 (GLP-1)
CL2012003641A1 (en) Analog glucagon compound comprising substitutions of amino acid residues in positions 3 and / or 4 of the native glucagon and having activity in the glucagon receptor and / or the glp-1 receptor; pharmaceutical composition comprising the compound; use of the compound to prevent weight gain or promote weight loss in a subject in need.
PE20140795A1 (en) COMPOSITION TO TREAT DIABETES INCLUDING A LONG-ACTING INSULIN CONJUGATE AND A LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE
PE20230404A1 (en) A CONJUGATE COMPRISING OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT, AND USE THEREOF
PE20160507A1 (en) DIFFERENTIATION OF MESENCHYMAL STEM CELLS
NZ612297A (en) Glucagon analogs exhibiting gip receptor activity
EA201201164A1 (en) PREPARATIONS ON THE BASIS OF ANALOGUES OF INSULIN OF PROLONGED ACTION IN SOLUBLE AND CRYSTALLINE FORMS
AR093903A1 (en) GLUCAGON AND GLP-1 COAGONISTS FOR THE TREATMENT OF OBESITY
AR092456A1 (en) FUSION PROTEINS FOR THE TREATMENT OF A METABOLIC SYNDROME
IN2012DN00377A (en)
PE20121636A1 (en) IL-2 DERIVED IMMUNOMODULATOR POLYPEPTIDES AND THEIR THERAPEUTIC USE IN CANCER AND CHRONIC INFECTIONS
HRP20140616T1 (en) Oxyntomodulin peptide analogue
WO2010100506A3 (en) Delivery system with scaffolds
RU2015144632A (en) THERAPEUTIC PEPTIDES
EP2548884A3 (en) Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
WO2011115420A3 (en) Adhesive extracellular matrix mimetic
CO6331291A2 (en) CRKL SIGNALING PEPTIDES

Legal Events

Date Code Title Description
FD Application declared void or lapsed